.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the public market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the symbolic representation “BIOA,” according to files filed with the Stocks and Substitution Percentage. The firm has actually not publicly discussed an anticipated monetary quantity for the offering.The clinical-stage firm proclaims lead prospect azelaprag, a by mouth delivered small particle slated to go into period 2 testing in combination along with semaglutide– sold by Novo Nordisk under trademark name Wegovy for weight reduction– in the first half of next year. Semaglutide is additionally marketed as Ozempic and also Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually developed to combine properly with GLP-1 medications, enhancing effective weight loss while maintaining muscular tissue mass. The investigational drug was found to be well-tolerated one of 265 individuals around eight stage 1 trials, depending on to BioAge.Recently, BioAge garnered the assistance of Lilly to manage a trial integrating azelaprag along with the Huge Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and also Zepbound for fat burning. The partners are actually currently conducting a phase 2 test of azelaprag and also tirzepatide, along with topline results expected in the third one-fourth of 2025.The biotech is actually likewise preparing a blood insulin sensitivity proof-of-concept trial determining azelaprag as a monotherapy in the very first one-half of upcoming year to support potential evidence expansion.
On top of that, the firm plans to talk to the FDA for permission in the second half of 2025 to launch individual screening for an NLRP3 inhibitor targeting metabolic diseases and neuroinflammation.BioAge’s foreseed relocate to everyone market observes a minor uptick in considered biotech IPOs coming from Bicara Therapies as well as Zenas Biopharma. Zooming out, the current IPO landscape is actually a “mixed photo,” with premium business still debuting on the public markets, just in lessened amounts, according to PitchBook.